First-line and Second-line Therapy of Zuberitamab in Idiopathic Membranous Nephropathy: A Single-center Retrospective Study
Zuberitamab was associated with favorable clinical and immunologic responses in patients with IMN, including those previously treated with rituximab. These findings support its potential role as a therapeutic option, warranting further validation in prospective studies.
Authors
- Fengmin Shao (ORCID: https://orcid.org/0000-0002-7534-1585)
- Lei Wang (ORCID: https://orcid.org/0000-0002-3024-8627)
- Lei Yan (ORCID: https://orcid.org/0000-0001-6548-1317)
- Miaomiao Yang (ORCID: https://orcid.org/0000-0002-3438-7958)
Institutions
- Henan Provincial People's Hospital (CN)
Publication Details
- Journal
- Kidney Medicine
- Published
- 2025-11-17
- DOI
- https://doi.org/10.1016/j.xkme.2025.101182
- Primary Topic
- Renal Diseases and Glomerulopathies
- Type
- article
- Field-Weighted Citation Impact
- 0.00